Deletions and/or loss-of-function mutations in SETD2 are also detected recurrently in different types of leukemia and solid tumors, including gastroesophageal cancers and lung adenocarcinoma (LUAD), though at lower frequency than seen in ccRCC (Zhu et al., 2014; Foggetti et al., 2021; Kadara et al., 2017; Walter et al., 2017; Mar et al., 2017). Here, SETD2 is linked to lung adenocarcinoma.